Insider Trading: Kindred Biosciences, Inc. (KIN)’s President and CEO Richard Chin Sold 1,930 shares; Dunkin Brands Group (DNKN) Sentiment Is 1.13

May 10, 2018 - By Winifred Garcia

Kindred Biosciences, Inc. (NASDAQ:KIN) Logo

Sentiment for Dunkin Brands Group Inc (DNKN)

Dunkin Brands Group Inc (DNKN) investors sentiment decreased to 1.13 in Q4 2017. It’s down -0.04, from 1.17 in 2017Q3. The ratio dived, as 154 institutional investors started new or increased stock positions, while 136 reduced and sold stakes in Dunkin Brands Group Inc. The institutional investors in our database now have: 77.82 million shares, down from 80.37 million shares in 2017Q3. Also, the number of institutional investors holding Dunkin Brands Group Inc in top ten stock positions increased from 1 to 2 for an increase of 1. Sold All: 45 Reduced: 91 Increased: 95 New Position: 59.

More notable recent Dunkin' Brands Group, Inc. (NASDAQ:DNKN) news were published by: Seekingalpha.com which released: “Is Dunkin’ Brands A Buy?” on May 07, 2018, also Seekingalpha.com with their article: “Key Takeaways From Dunkin’s Earnings Call” published on May 07, 2018, Nasdaq.com published: “Should You Be Shorting Dunkin’ Donuts or Burger King Parent QSR?” on May 07, 2018. More interesting news about Dunkin' Brands Group, Inc. (NASDAQ:DNKN) were released by: Seekingalpha.com and their article: “Dunkin’ Brands reports negative comp in US” published on April 26, 2018 as well as Nasdaq.com‘s news article titled: “McDonald’s Stays on Top With Industry-Leading Sales Growth” with publication date: May 02, 2018.

Ratings analysis reveals 40% of Dunkin Brands’s analysts are positive. Out of 5 Wall Street analysts rating Dunkin Brands, 2 give it “Buy”, 1 “Sell” rating, while 2 recommend “Hold”. The lowest target is $54.0 while the high is $57.0. The stock’s average target of $55.50 is -13.23% below today’s ($63.96) share price. DNKN was included in 5 notes of analysts from September 27, 2016. The stock of Dunkin' Brands Group, Inc. (NASDAQ:DNKN) earned “Outperform” rating by Credit Suisse on Tuesday, November 29. Maxim Group maintained Dunkin' Brands Group, Inc. (NASDAQ:DNKN) rating on Tuesday, September 27. Maxim Group has “Buy” rating and $57.0 target. On Monday, October 17 the stock rating was downgraded by RBC Capital Markets to “Sector Perform”. The rating was maintained by Wedbush with “Neutral” on Friday, February 10. The stock of Dunkin' Brands Group, Inc. (NASDAQ:DNKN) has “Underperform” rating given on Wednesday, January 4 by Jefferies.

Mcrae Capital Management Inc holds 4.21% of its portfolio in Dunkin' Brands Group, Inc. for 154,792 shares. Gillespie Robinson & Grimm Inc owns 445,569 shares or 3.63% of their US portfolio. Moreover, Benin Management Corp has 2.47% invested in the company for 95,425 shares. The Connecticut-based Halsey Associates Inc Ct has invested 2.17% in the stock. Davis R M Inc, a Maine-based fund reported 710,167 shares.

Since January 1, 0001, it had 0 insider buys, and 13 insider sales for $32.80 million activity.

The stock decreased 1.24% or $0.8 during the last trading session, reaching $63.96. About 1.06M shares traded. Dunkin' Brands Group, Inc. (DNKN) has risen 6.77% since May 10, 2017 and is uptrending. It has underperformed by 4.78% the S&P500.

DunkinÂ’ Brands Group, Inc., together with its subsidiaries, develops, franchises, and licenses quick service restaurants under the DunkinÂ’ Donuts and Baskin-Robbins brands worldwide. The company has market cap of $5.29 billion. The firm operates through four divisions: DunkinÂ’ Donuts U.S., DunkinÂ’ Donuts International, Baskin-Robbins International, and Baskin-Robbins U.S. It has a 16.83 P/E ratio. The Company’s restaurants offer hot and cold coffee, baked goods, donuts, bagels, muffins, breakfast sandwiches, hard-serve ice cream, soft serve ice cream, frozen yogurt, shakes, malts, floats, and cakes.

Among 7 analysts covering Kindred Biosciences (NASDAQ:KIN), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Kindred Biosciences has $1200 highest and $7.50 lowest target. $9.80’s average target is 1.55% above currents $9.65 stock price. Kindred Biosciences had 14 analyst reports since November 17, 2015 according to SRatingsIntel. C.L. King initiated Kindred Biosciences, Inc. (NASDAQ:KIN) on Wednesday, December 27 with “Hold” rating. The rating was maintained by H.C. Wainwright on Friday, March 2 with “Buy”. The firm earned “Buy” rating on Tuesday, May 30 by FBR Capital. BMO Capital Markets downgraded the stock to “Market Perform” rating in Tuesday, November 17 report. The rating was initiated by Ladenburg Thalmann with “Buy” on Tuesday, November 1. The rating was maintained by BMO Capital Markets with “Hold” on Monday, August 7. The stock has “Buy” rating by FBR Capital on Tuesday, June 27. H.C. Wainwright maintained the shares of KIN in report on Wednesday, May 9 with “Buy” rating. The stock has “Buy” rating by FBR Capital on Monday, February 26. KeyBanc Capital Markets downgraded the shares of KIN in report on Friday, November 18 to “Sector Weight” rating.

Investors sentiment decreased to 0.93 in Q4 2017. Its down 1.31, from 2.24 in 2017Q3. It turned negative, as 12 investors sold Kindred Biosciences, Inc. shares while 16 reduced holdings. 8 funds opened positions while 18 raised stakes. 17.44 million shares or 4.61% less from 18.28 million shares in 2017Q3 were reported. State Street Corp reported 0% stake. Granahan Mngmt Ma owns 126,518 shares or 0.09% of their US portfolio. Dimensional Fund Limited Partnership holds 0.01% or 1.36 million shares in its portfolio. Bnp Paribas Arbitrage Sa invested 0% of its portfolio in Kindred Biosciences, Inc. (NASDAQ:KIN). Prudential Financial invested 0% of its portfolio in Kindred Biosciences, Inc. (NASDAQ:KIN). Tiaa Cref Inv Ltd Liability holds 0% or 61,427 shares in its portfolio. Grp One Trading Limited Partnership has 29,403 shares for 0% of their portfolio. Legal And General Group Incorporated Public Limited Company has 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN). Manufacturers Life Insurance The has 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN) for 22,105 shares. Renaissance Technologies Limited reported 727,063 shares stake. Parallax Volatility Advisers Lp owns 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN) for 3,360 shares. Connor Clark Lunn Limited holds 0% of its portfolio in Kindred Biosciences, Inc. (NASDAQ:KIN) for 78,375 shares. California State Teachers Retirement Systems invested 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). Susquehanna International Group Llp stated it has 0% of its portfolio in Kindred Biosciences, Inc. (NASDAQ:KIN). California-based Ecor1 Cap Limited Company has invested 0.58% in Kindred Biosciences, Inc. (NASDAQ:KIN).

The stock decreased 0.52% or $0.05 during the last trading session, reaching $9.65. About 713,592 shares traded or 600.44% up from the average. Kindred Biosciences, Inc. (NASDAQ:KIN) has risen 18.31% since May 10, 2017 and is uptrending. It has outperformed by 6.76% the S&P500.

The Kindred Biosciences Inc’s President and CEO, Richard Chin, the well informed person unloaded – 1,930 Kindred Biosciences Inc’s shares, based on the avg market share price which was $10.0 for a share. The shares had a value of $19,317 U.S Dollars. He also unloaded 20,000 shares with a total value of about $181,000 USD in the last month. Today, Richard Chin owns 2.24 million shares which are about 10%+ of Kindred Biosciences Inc’s total market cap.

More notable recent Kindred Biosciences, Inc. (NASDAQ:KIN) news were published by: Bizjournals.com which released: “This Peninsula company’s new drug is the cat’s meow — the FDA says so” on May 07, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: Valeant Earnings, Lipocine’s FDA Watch, Invivo CFO Departure” published on May 08, 2018, Prnewswire.com published: “Kindred Biosciences Announces First Quarter 2018 Financial Results” on May 08, 2018. More interesting news about Kindred Biosciences, Inc. (NASDAQ:KIN) were released by: Streetinsider.com and their article: “Kindred Biosciences (KIN) Provides Updates on Pending Drug Approvals” published on April 24, 2018 as well as Streetinsider.com‘s news article titled: “Kindred Biosciences (KIN) Appoints Dr. Ernest Mario and Dr. Joseph McCracken to Board” with publication date: April 25, 2018.

Kindred Biosciences, Inc. (NASDAQ:KIN) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>